{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Blood+Cell+Disorders&page=7",
    "query": {
      "condition": "Human Blood Cell Disorders",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 192,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Blood+Cell+Disorders&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Blood+Cell+Disorders&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T13:40:59.790Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00018018",
      "title": "Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "CD34+ cells transduced with ADA retrovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Month and older"
      },
      "enrollment_count": 8,
      "start_date": "2001-06-20",
      "completion_date": "2014-09-17",
      "has_results": false,
      "last_update_posted_date": "2019-12-12",
      "last_synced_at": "2026-10-21T13:40:59.790Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00018018"
    },
    {
      "nct_id": "NCT05867056",
      "title": "Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis B, Chronic"
      ],
      "interventions": [
        {
          "name": "IMC-I109V Single Ascending Dose",
          "type": "DRUG"
        },
        {
          "name": "IMC-I109V Multiple Ascending Doses",
          "type": "DRUG"
        },
        {
          "name": "HBV HCC Module MAD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immunocore Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2020-08-12",
      "completion_date": "2024-12-15",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-10-21T13:40:59.790Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Cleveland, Ohio",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05867056"
    },
    {
      "nct_id": "NCT03899480",
      "title": "Adoptive Transfer of Haploidentical NK Cells and N-803",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hiv",
        "HIV Infections",
        "Immune Deficiency"
      ],
      "interventions": [
        {
          "name": "Haploidentical Natural Killer (NK) Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 9,
      "start_date": "2019-05-01",
      "completion_date": "2021-04-01",
      "has_results": false,
      "last_update_posted_date": "2021-04-23",
      "last_synced_at": "2026-10-21T13:40:59.790Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03899480"
    },
    {
      "nct_id": "NCT05652335",
      "title": "A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory Multiple Myeloma",
        "Previously Treated Amyloid Light-chain (AL) Amyloidosis"
      ],
      "interventions": [
        {
          "name": "JNJ-79635322",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2022-11-22",
      "completion_date": "2030-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-21T13:40:59.790Z",
      "location_count": 9,
      "location_summary": "Duarte, California • Irvine, California • San Francisco, California + 5 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05652335"
    },
    {
      "nct_id": "NCT07226843",
      "title": "A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin's",
        "Lymphoma, Diffuse Large B-Cell",
        "Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "LY4584180",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 460,
      "start_date": "2026-04-17",
      "completion_date": "2030-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-21T13:40:59.790Z",
      "location_count": 21,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07226843"
    },
    {
      "nct_id": "NCT04192487",
      "title": "Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acquired Immunodeficiency Syndrome",
        "Healthy Volunteers",
        "HIV/AIDS",
        "HIV Diarrhea",
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Crofelemer delayed-release tablets 125mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Napo Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2019-10-22",
      "completion_date": "2021-08-31",
      "has_results": false,
      "last_update_posted_date": "2021-10-22",
      "last_synced_at": "2026-10-21T13:40:59.790Z",
      "location_count": 3,
      "location_summary": "Tustin, California • Stratford, Connecticut • Springfield, Massachusetts",
      "locations": [
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Stratford",
          "state": "Connecticut"
        },
        {
          "city": "Springfield",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04192487"
    },
    {
      "nct_id": "NCT07602166",
      "title": "Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Salt Sensitivity of Blood Pressure",
        "High Blood Pressure",
        "Inflammation",
        "Renin-Angiotensin-Aldosterone System"
      ],
      "interventions": [
        {
          "name": "2-hydroxybenzylamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-09",
      "completion_date": "2031-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-21T13:40:59.790Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07602166"
    },
    {
      "nct_id": "NCT00006444",
      "title": "The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections",
        "Papilloma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "13 Years and older · Female only"
      },
      "enrollment_count": 160,
      "start_date": "2000-11",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2013-11-20",
      "last_synced_at": "2026-10-21T13:40:59.790Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006444"
    },
    {
      "nct_id": "NCT05153330",
      "title": "Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Acute Mixed-Phenotype Leukemia",
        "Cancer",
        "Refractory",
        "Progression",
        "Diffuse Large B Cell Lymphoma",
        "Multiple Myeloma",
        "Lymphoma",
        "Lymphoma, Non-Hodgkin",
        "Myeloma, Plasma-Cell",
        "Myelomatosis",
        "Plasma Cell Myeloma",
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "BMF-219",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biomea Fusion Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2022-01-24",
      "completion_date": "2025-05-02",
      "has_results": false,
      "last_update_posted_date": "2025-07-03",
      "last_synced_at": "2026-10-21T13:40:59.790Z",
      "location_count": 17,
      "location_summary": "Irvine, California • Los Angeles, California • Sacramento, California + 13 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05153330"
    },
    {
      "nct_id": "NCT02689453",
      "title": "Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "T-Cell Lymphoma Relapsed",
        "Adult T-Cell Leukemia (ATL)",
        "Peripheral T-Cell Lymphoma (PTCL)",
        "Cutaneous T Cell Lymphoma (CTCL)",
        "T-Cell Prolymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "IL-15 plus",
          "type": "BIOLOGICAL"
        },
        {
          "name": "alemtuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2017-01-19",
      "completion_date": "2021-06-15",
      "has_results": true,
      "last_update_posted_date": "2022-04-29",
      "last_synced_at": "2026-10-21T13:40:59.790Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02689453"
    }
  ]
}